Loading...
•
Sep 30, 2023
Xeris Biopharma Q3 2023 Earnings Report
Achieved record revenue with a significant increase from the prior year and prior quarter, while tightening full-year revenue guidance and maintaining focus on cash flow breakeven.
Key Takeaways
Xeris Biopharma reported record revenue of $48.3 million for the third quarter of 2023, a 27% increase from the previous quarter and a 63% increase from the same period last year. The company has tightened its full-year 2023 revenue guidance to $160 million - $165 million and is on track to achieve cash flow breakeven in the fourth quarter.
Record revenue of $48.3 million, a 27% increase from prior quarter and a 63% increase from the same period prior year.
Tightened full-year 2023 revenue guidance from $155 million-$165 million to $160 million-$165 million.
Ended Q3 with $66.0 million in cash, cash equivalents and short-term investments.
Remains on track to achieve cash flow breakeven in the fourth quarter.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Revenue by Segment
Recorlev Revenue
CapyFin.comGvoke Revenue
CapyFin.comKeveyis Revenue
CapyFin.com Forward Guidance
The company has tightened its full-year 2023 revenue guidance to $160 million - $165 million and is on track to achieve cash flow breakeven in the fourth quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income